To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer

NCT02238366 ·Status: COMPLETED

Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy

NCT03516110 ·Status: COMPLETED

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

NCT00036543 ·Status: COMPLETED ·Phase: PHASE3

Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State

NCT01560858 ·Status: COMPLETED

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

NCT01957436 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

NCT00286806 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

NCT00286793 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer

NCT00668083 ·Status: COMPLETED

Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.

NCT01123434 ·Status: COMPLETED

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer

NCT02066961 ·Status: COMPLETED

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

NCT05169112 ·Status: RECRUITING ·Phase: PHASE3

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

NCT00313781 ·Status: COMPLETED ·Phase: PHASE2

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

NCT01732549 ·Status: TERMINATED ·Phase: PHASE2

Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

NCT00172055 ·Status: COMPLETED ·Phase: PHASE3

Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

NCT00128531 ·Status: COMPLETED ·Phase: PHASE3

A Long Term Safety Study With Atrasentan

NCT00127478 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

NCT00541281 ·Status: COMPLETED ·Phase: PHASE2

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

NCT06473259 ·Status: RECRUITING

Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer

NCT02853409 ·Status: COMPLETED

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

NCT04181203 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database

NCT06902441 ·Status: COMPLETED

Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer Treatment

NCT06217770 ·Status: COMPLETED

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

NCT06824818 ·Status: RECRUITING ·Phase: NA

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

NCT00493766 ·Status: TERMINATED ·Phase: PHASE1